Page 2 - One Codex News Today : Breaking News, Live Updates & Top Stories | Vimarsana

This story is available exclusively to Insider subscribers. Become an Insider and start reading now. 23andMe in February said it's going public in a deal that values the company at $3.5 billion.  Despite 23andMe's success, the consumer genomics market has largely bottomed out, an analyst said. Others hoping to cash in on genetic health assessments have pivoted or shuttered efforts altogether. As consumer genetics giant 23andMe prepares to go public, the personal genetics market isn't what it once was.  "We've kind of hit the bottom and we're stable right ...

The company unveiled its inaugural ESG report. But the overall rise in growth stocks was its main catalyst.

expected to reach USD 1.72 billion by 2028 registering a CAGR of 15.02%, according to a new report by Grand View Research, Inc. Key drivers contributing to market expansion include the growing adoption of sequencing platforms for clinical diagnosis because of a significant reduction in the cost of installation. The easy availability of genomic and proteomic data is also expected to create lucrative growth opportunities in this market during the forecast period. Key suggestions from the report: Services dominated the products segment in 2020 and will retain the leading position growing at th...

Transnetyx, One Codex Build Strategic Partnership to Provide a Complete Microbiome Analysis Service for Both Mice and Humans News provided by Share this article Share this article MEMPHIS, Tenn., Jan. 27, 2021 /PRNewswire/ -- Transnetyx, Inc. announced today its collaboration with One Codex on an end-to-end microbiome sequencing and analysis service. This offering will be driven by Transnetyx's wide-reaching global footprint in the model organism community and One Codex's deep expertise in the microbiome. (PRNewsfoto/Transnetyx) Transnetyx, Inc. announced today its collaboration with One Co...